NCT04020809View on ClinicalTrials.gov

Neoadjuvant Atezolizumab in Cutaneous Melanoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

September 25, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Cutaneous Melanoma

Interventions

DRUG

Atezolizumab

Anti-PD-L1 monoclonal antibody

Trial Locations (1)

77030

Houston Methodist Hospital, Houston

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER